BIOS Capital Management LP Invests $2.21 Million in IN8bio, Inc. (NASDAQ:INAB)

BIOS Capital Management LP bought a new position in shares of IN8bio, Inc. (NASDAQ:INAB) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 8,600,001 shares of the company’s stock, valued at approximately $2,212,000. IN8bio comprises approximately 2.3% of BIOS Capital Management LP’s investment portfolio, making the stock its 6th biggest holding. BIOS Capital Management LP owned 0.12% of IN8bio at the end of the most recent reporting period.

Separately, Sigma Planning Corp lifted its position in shares of IN8bio by 42.0% during the third quarter. Sigma Planning Corp now owns 851,280 shares of the company’s stock worth $230,000 after purchasing an additional 251,600 shares during the last quarter. Hedge funds and other institutional investors own 92.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their price objective on IN8bio from $8.00 to $6.00 and set a “buy” rating for the company in a report on Friday.

IN8bio Stock Performance

INAB stock opened at $0.23 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.84 and a quick ratio of 1.84. The business has a 50-day moving average price of $0.28 and a 200 day moving average price of $0.30. The company has a market capitalization of $18.32 million, a P/E ratio of -0.30 and a beta of 0.03. IN8bio, Inc. has a 1-year low of $0.21 and a 1-year high of $1.74.

IN8bio (NASDAQ:INAB) last announced its earnings results on Thursday, March 13th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. As a group, equities research analysts forecast that IN8bio, Inc. will post -0.56 EPS for the current fiscal year.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.